Understand the source comparison
Comparison: Dihexa vs Other Pro-Cognitive Research Compounds
Dihexa HGF/c-Met receptor agonism → BDNF upregulation High (crosses passively) 0.5–5 mg/kg subcutaneous Alzheimer's models, TBI, stroke, aging Most potent BDNF pathway activator studied; small-molecule advantage for systemic dosing BDNF (native protein) Direct
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dihexa
- HGF/c-Met receptor agonism → BDNF upregulation
- High (crosses passively)
- 0.5–5 mg/kg subcutaneous
- Alzheimer's models, TBI, stroke, aging
- Most potent BDNF pathway activator studied; small-molecule advantage for systemic dosing
- BDNF (native protein)
- Direct TrkB receptor activation
- None (requires ICV injection)
- 1–10 µg ICV
- Synaptic plasticity studies
- Gold standard mechanism but clinically impractical delivery
- NSI-189
- Hippocampal neurogenesis stimulation
- Moderate
- 10–40 mg/kg oral
- Depression models, hippocampal volume studies
- Neurogenic focus distinct from BDNF signaling; Phase 2 human trial data available
- Semax
- ACTH(4-10) analog, upregulates neurotrophins
- Moderate (nasal administration)
- 50–300 µg/kg intranasal
- Neuroprotection, attention, memory
- Established clinical use in some regions; less potent than dihexa at BDNF upregulation
- Cerebrolysin
- Neurotrophic peptide mixture
- Low (peripheral administration limited)
- 2.5–5 mL/kg IV
- Stroke recovery, dementia
- Multimodal but undefined mechanism; variable batch composition